The purpose of the study is to assess how satisfied patients are with using Zeqmelit™ compared to their usual treatment, especially during an acute allergic reaction. Participants in the study will use the mouth-dissolving film and provide feedback on their overall satisfaction, including how safe they feel using it. The study will also gather information on the participants’ experiences with the treatment, such as their choice of treatment and access to it, as well as their perception of its effectiveness.

Throughout the study, participants will be asked to answer questions about their satisfaction and experiences with the treatment. This will help researchers understand how Zeqmelit™ compares to standard treatments for acute allergic reactions. The study is designed to be low-intervention, meaning it aims to minimize any disruption to the participants’ usual treatment routines.

The study involves applying these different solutions to the skin to observe the physical response. This response is measured by looking at the wheal, which is a small, raised, itchy bump on the skin that appears during an allergic reaction. By measuring the size of these bumps, the relationship between the amount of pollen extract and the body’s reaction can be determined. The process helps to ensure that the pollen extracts used in medical settings are consistent and reliable.

Participants in this study will be people who have a history of delayed allergic reactions to penicillin, meaning their symptoms appeared more than six hours after taking the medication, or people who are unsure about when their reaction occurred. All participants will first receive a single test dose of amoxicillin. Those who tolerate this first dose without problems will then be randomly assigned to receive either amoxicillin capsules or placebo capsules for five days. Neither the participants nor the doctors will know which treatment each person is receiving during the study.

The study will monitor participants for any allergic reactions that occur up to seven days after the first test dose, with additional monitoring continuing up to fourteen days. Participants will have follow-up appointments either through telehealth or in person at the clinic. An independent panel of experts who do not know which treatment participants received will review any reactions to determine if they are truly immune-mediated allergic reactions. The study will also measure how the testing affects participants’ quality of life using a questionnaire at the beginning of the study and again at ninety days.

The study involves using a skin-prick test solution containing different concentrations of Lepidoglyphus destructor extract. During the test, small amounts of the solution are placed on the skin through tiny pricks. The test also includes a histamine dihydrochloride solution as a positive control and a sodium chloride solution (salt water) as a negative control to ensure accurate results.

The testing procedure involves measuring the skin’s reaction to different strengths of the extract. The skin reaction appears as a small raised area called a wheal, which is measured to determine how well the extract works in identifying allergies. The study takes place over a single day for each participant, with careful monitoring for any allergic reactions during the testing period.

The study involves using various concentrations of the allergen extract through intraepidermal application, which means the solution is applied just under the surface of the skin. During the testing, histamine dihydrochloride will be used as a positive control substance, and sodium chloride (salt water) as a negative control to ensure accurate results. The skin’s reaction to these substances will be measured and compared.

The purpose of this research is to establish the correct concentration of the allergen extract that produces a skin reaction comparable to a standard allergic response. This will help determine the proper strength of the extract for future use in allergy testing. The study will also monitor any unwanted reactions that might occur during the testing process to ensure the safety of the procedure.

The medications are designed to treat allergies by blocking the effects of histamine in the body. Each medication is taken by mouth in the form of a tablet that dissolves on the tongue. During the study, participants will receive each of the three medications and placebo at different times, with appropriate breaks between treatments.

The study will measure how well each medication prevents the development of raised, itchy bumps and redness on the skin after histamine exposure. Researchers will monitor participants’ reactions at various time points after taking the medication to understand how quickly each drug starts working, how long the effects last, and how strong the effects are compared to placebo.

Participants in the study will undergo skin-prick tests where small amounts of the allergenic extracts are applied to the skin. The reaction is measured by the size of the wheal, which is a small, raised area on the skin. This helps in determining the dose-response relationship, which is how the skin reacts to different concentrations of the allergen. The study will also assess the safety of these extracts by monitoring any adverse reactions that may occur during the testing process.

The trial is designed to provide valuable information on the effectiveness and safety of these allergenic extracts, which could help in better managing allergies related to dust mites. The study is expected to run until April 2025, with recruitment starting in January 2025. Participants will be selected based on specific criteria, including a confirmed allergy to the dust mites being studied. The results of this trial could lead to improved treatments for individuals suffering from dust mite allergies.

The purpose of the study is to determine the biological activity of these mite extracts in patients who are sensitive to them. This means the study aims to find out how strong the reaction is when these extracts are used in a skin-prick test. The study will involve applying these extracts to the skin and observing the size of the reaction, or wheal, that forms. This will help in standardizing the extracts in terms of their biological activity, measured in Histamine Equivalent Units (HEP).

Participants in the study will undergo skin-prick tests with the mite extracts and the histamine solution. The size of the skin reaction will be measured to assess the potency of the extracts. The study will also monitor for any adverse reactions to ensure safety. The trial is designed to help improve the understanding and standardization of allergy testing for these specific mite allergens.

The study will be conducted in two phases. In the first phase, the concentration of the Dermatophagoides pteronyssinus extract will be determined. In the second phase, the study will assess how sensitive and specific the extract is in detecting allergies. This means the study will check how well the extract can identify people who are allergic and those who are not. The study will also use a positive control, which is a solution of histamine dihydrochloride, and a negative control, which is a solution of sodium chloride, to compare the reactions.

Participants in the study will undergo skin-prick tests where small amounts of the allergenic extract, positive control, and negative control are applied to the skin. The size of the reaction, known as a wheal, will be measured to determine the effectiveness of the allergenic extract. The study aims to ensure that the extract is both safe and reliable for diagnosing allergies to Dermatophagoides pteronyssinus and its related species, Dermatophagoides farinae.